Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > ORGANIZATION
ORGANIZATION
- JPWA to File Notification to Form Cartel for Uniform Tax Display Method
January 31, 2014
- JPMA Drafting New Rules that Would Restrict Grants and Endowments by Drug Makers to Research Not Involving Their Own Products
January 28, 2014
- Medwatcher Raps Ministry Subcommittees’ Conclusion on HPV Vaccine Side Effects
January 27, 2014
- Generic Industry Can’t Afford “Backsliding” Following FY2014 NHI Pricing Reform: JGA President Yoshida
January 27, 2014
- Dr Teshirogi of JPMA Expresses Concern About Impact of New Price Reduction Rule on Stable Supplies of Long-Listed Drugs, Generics
January 17, 2014
- Generic Makers Likely to Disclose Payments to Medical Institutions from Early May
January 15, 2014
- JPWA Chair Weighs Cartel Deal to Unify Tax Display Methods after Sales Levy Hike
January 14, 2014
- Next Drug Price Revision Won’t Help Promote Generic Use, JGA President Says
January 9, 2014
- Japan CRO Association Announces Report on Quality Assurance of Subcontracted Services
January 9, 2014
- New Price Cut for Long-Listed Products “Harsh,” Needs Follow-Up Review: FPMAJ Chair Naito
January 1, 2014
- New Price Cut Rule for Long-Listed Products Will Wreak Havoc on Pharmas: FPMAJ Chair
December 27, 2013
- Osaka Bio Fund to Invest 150 Million Yen in Genomix
December 26, 2013
- Mr Koshimizu of MREAC Expresses Concern about Increasing Number of MSLs at a Seminar on Recertification of Managers in Charge of MR Education
December 24, 2013
- Sanofi’s Moulding Picked as New Chair of EFPIA Japan
December 17, 2013
- FPMAJ Chief Renews His Calls to Institutionalize Premium
December 16, 2013
- JPMA Revises Rules for Preparing Product Information Brochures for the 1st Time in 5 years; Bans “Emphasis on Differences” from and “Slander” of Competitors’ Products
December 13, 2013
- Head of JAMS COI Committee Proposes Legislating Ethical Guidelines for Clinical Research
December 11, 2013
- CSIMC Continues to Fire Barbs at “Precursor Premium” Despite Industry Appeal
December 10, 2013
- Mr Umeda of PhRMA Opposes Proposal to Revise Foreign Average Price Adjustment Rule
December 10, 2013
- JGA President Prefers 60% Rule for NHI Generic Prices, Fails to Gain Support on Five Generic Price Ranges
December 9, 2013
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…